Cargando…
Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers
Amplicon-based next generation sequencing (NGS) approaches have been preferentially adopted by the clinical laboratories on the basis of a short turnaround time (TAT) and small DNA input needs. However, little work has been done to assess the amplicon-based NGS methods for copy number variation (CNV...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471150/ https://www.ncbi.nlm.nih.gov/pubmed/32621174 http://dx.doi.org/10.1007/s12253-020-00844-w |
_version_ | 1783578723270787072 |
---|---|
author | Niu, Dongfeng Li, Lei Yu, Yang Zang, Wanchun Li, Zhongwu Zhou, Lixin Jia, Ling Rao, Guanhua Gao, Lianju Cheng, Gang Ji, Ke Lin, Dongmei |
author_facet | Niu, Dongfeng Li, Lei Yu, Yang Zang, Wanchun Li, Zhongwu Zhou, Lixin Jia, Ling Rao, Guanhua Gao, Lianju Cheng, Gang Ji, Ke Lin, Dongmei |
author_sort | Niu, Dongfeng |
collection | PubMed |
description | Amplicon-based next generation sequencing (NGS) approaches have been preferentially adopted by the clinical laboratories on the basis of a short turnaround time (TAT) and small DNA input needs. However, little work has been done to assess the amplicon-based NGS methods for copy number variation (CNV) detection in comparison with current standard methods like immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). The correlation between NGS based CNV detection and the later standard methods has remained unexplored. We developed an amplicon-based panel to detect human epidermal receptor growth factor (HER2) amplification in formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from 280 breast cancer and 50 gastric cancer patients. Assessment by IHC and FISH was conducted in parallel, and descriptive statistics were used to assess the concordance. The copy number detected by NGS was correlated with either the average HER2 copy number (signals/cell) (r = 0.844; p < 0.001) or the HER2/CEP17 ratio (r = 0.815; p < 0.001). We determined a cut-off value for NGS to categorize HER2 amplification status by using 151 HER2 non-amplified FFPE samples. In breast cancer patients, the cut-off value was 2.910, with 95.35%, 98.67% and 97.29% sensitivity, specificity and concordance, respectively. However, this cut-off value displayed low sensitivity in gastric cancer patients (64.71%), and the following macrodissection procedure was not effective for increasing sensitivity (57.14%). Evaluation of HER2 copy number with NGS in our study was comparable with IHC and FISH in breast cancer patients, but concordance in gastric cancer was only moderate. The greater discordance in gastric cancer may reflect the underlying biological mechanisms, and further study is warranted. NGS-based HER2 assessment may decrease the equivocal HER2 determinations in breast cancer patients assessed by FISH/IHC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12253-020-00844-w) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7471150 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-74711502020-09-16 Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers Niu, Dongfeng Li, Lei Yu, Yang Zang, Wanchun Li, Zhongwu Zhou, Lixin Jia, Ling Rao, Guanhua Gao, Lianju Cheng, Gang Ji, Ke Lin, Dongmei Pathol Oncol Res Original Article Amplicon-based next generation sequencing (NGS) approaches have been preferentially adopted by the clinical laboratories on the basis of a short turnaround time (TAT) and small DNA input needs. However, little work has been done to assess the amplicon-based NGS methods for copy number variation (CNV) detection in comparison with current standard methods like immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). The correlation between NGS based CNV detection and the later standard methods has remained unexplored. We developed an amplicon-based panel to detect human epidermal receptor growth factor (HER2) amplification in formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from 280 breast cancer and 50 gastric cancer patients. Assessment by IHC and FISH was conducted in parallel, and descriptive statistics were used to assess the concordance. The copy number detected by NGS was correlated with either the average HER2 copy number (signals/cell) (r = 0.844; p < 0.001) or the HER2/CEP17 ratio (r = 0.815; p < 0.001). We determined a cut-off value for NGS to categorize HER2 amplification status by using 151 HER2 non-amplified FFPE samples. In breast cancer patients, the cut-off value was 2.910, with 95.35%, 98.67% and 97.29% sensitivity, specificity and concordance, respectively. However, this cut-off value displayed low sensitivity in gastric cancer patients (64.71%), and the following macrodissection procedure was not effective for increasing sensitivity (57.14%). Evaluation of HER2 copy number with NGS in our study was comparable with IHC and FISH in breast cancer patients, but concordance in gastric cancer was only moderate. The greater discordance in gastric cancer may reflect the underlying biological mechanisms, and further study is warranted. NGS-based HER2 assessment may decrease the equivocal HER2 determinations in breast cancer patients assessed by FISH/IHC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12253-020-00844-w) contains supplementary material, which is available to authorized users. Springer Netherlands 2020-07-03 2020 /pmc/articles/PMC7471150/ /pubmed/32621174 http://dx.doi.org/10.1007/s12253-020-00844-w Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Article Niu, Dongfeng Li, Lei Yu, Yang Zang, Wanchun Li, Zhongwu Zhou, Lixin Jia, Ling Rao, Guanhua Gao, Lianju Cheng, Gang Ji, Ke Lin, Dongmei Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers |
title | Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers |
title_full | Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers |
title_fullStr | Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers |
title_full_unstemmed | Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers |
title_short | Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers |
title_sort | evaluation of next generation sequencing for detecting her2 copy number in breast and gastric cancers |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471150/ https://www.ncbi.nlm.nih.gov/pubmed/32621174 http://dx.doi.org/10.1007/s12253-020-00844-w |
work_keys_str_mv | AT niudongfeng evaluationofnextgenerationsequencingfordetectingher2copynumberinbreastandgastriccancers AT lilei evaluationofnextgenerationsequencingfordetectingher2copynumberinbreastandgastriccancers AT yuyang evaluationofnextgenerationsequencingfordetectingher2copynumberinbreastandgastriccancers AT zangwanchun evaluationofnextgenerationsequencingfordetectingher2copynumberinbreastandgastriccancers AT lizhongwu evaluationofnextgenerationsequencingfordetectingher2copynumberinbreastandgastriccancers AT zhoulixin evaluationofnextgenerationsequencingfordetectingher2copynumberinbreastandgastriccancers AT jialing evaluationofnextgenerationsequencingfordetectingher2copynumberinbreastandgastriccancers AT raoguanhua evaluationofnextgenerationsequencingfordetectingher2copynumberinbreastandgastriccancers AT gaolianju evaluationofnextgenerationsequencingfordetectingher2copynumberinbreastandgastriccancers AT chenggang evaluationofnextgenerationsequencingfordetectingher2copynumberinbreastandgastriccancers AT jike evaluationofnextgenerationsequencingfordetectingher2copynumberinbreastandgastriccancers AT lindongmei evaluationofnextgenerationsequencingfordetectingher2copynumberinbreastandgastriccancers |